Mebendazole (MBZ) is a synthetic broad-spectrum benzimidazole-derivative anthelmintic drug included in the WHO Model List of Essential Drugs and classified as a class II drug of the Biopharmaceutics Classification System, due to its poor solubility in water but high permeability. Here, we aim to obtain a new solid material that prevents the tautomeric interconversion between the pharmaceutical preferred form C of the drug and its inactive form A, and exhibiting solubility and dissolution profiles similar to that of MBZ C.
We rational designed a new material on the basis of the high statistical probability of formation of a 𝑅 2 2 (8) -type supramolecular synthon between MBZ and sulfonates. This motif was found in all reported structures of multicomponent systems of MBZ with oxoanionic coformers. The synthesis was performed by slow solvent evaporation from an equimolar solution of MBZ and p-toluenesulfonic acid (TsOH, an FDA accepted coformer) monohydrate in methanol. SC-synchrotron XRD experiment for the structure resolution of the new solid, named MBZH·TsO·H2O, was performed on the MANACA beamline at Sirius (Brazil). As expected, proton transfer and the formation of a 𝑅 motif, driven by hydrogen bonds as the main intermolecular 2 2 (8) interactions, were confirmed. A water molecule is also found in the crystal structure. This salt is stable up to 104 °C when the endothermic dehydration of the material takes place, yielding a new crystalline phase that was identified as the anhydride MBZH·TsO salt. Second event starts at 172 °C and is associated with the endothermic loss of the ester moiety of the drug. Further experiments are being conducted to fully characterized both new materials.